Wendy Lea
About Wendy Lea
Wendy Lea is a Staff Scientist at the National Institutes of Health, where she has worked since 2010. She specializes in biophysical characterization and assay design, contributing to large-scale high-throughput screening and evaluating novel assay platforms.
Work at National Institutes of Health
Wendy Lea has been employed at the National Institutes of Health (NIH) since 2010, currently holding the position of Staff Scientist. In this role, she has contributed significantly to biophysical characterization and assay design. Her responsibilities include developing and executing biochemical and cell-based assays for large-scale high-throughput screening across diverse chemical spaces. Prior to her current position, she worked as a Postdoctoral Fellow at NIH from 2007 to 2010, where she gained valuable experience in research and assay development.
Education and Expertise
Wendy Lea earned her Doctor of Philosophy in Biochemical Engineering from the University of Maryland Baltimore County, completing her studies from 2004 to 2007. This academic background has equipped her with a strong foundation in biochemical principles and methodologies, which she applies in her current research at the NIH. Her expertise includes evaluating novel assay platforms and technologies, enhancing the efficiency and effectiveness of biochemical assays.
Background
Wendy Lea's professional journey in the field of biochemistry began with her doctoral studies at the University of Maryland Baltimore County. Following her graduation, she joined the National Institutes of Health as a Postdoctoral Fellow, where she developed her skills in assay design and biophysical characterization. After three years in this role, she transitioned to a Staff Scientist position, where she has continued to advance her research and contribute to the scientific community.
Research Contributions
In her role at the National Institutes of Health, Wendy Lea has made notable contributions to the field of biochemistry through her work on biochemical and cell-based assays. She has been involved in large-scale high-throughput screening projects, which are critical for drug discovery and development. Her efforts in evaluating novel assay platforms and technologies have played a key role in enhancing research capabilities at NIH.